US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

12.53

-0.1300-1.03%

Volume:35.49K

Turnover:444.26K

Market Cap:454.74M

PE:-4.80

High:12.60

Open:12.60

Low:12.44

Close:12.66

52wk High:33.20

52wk Low:10.47

Shares:36.29M

Float Shares:19.98M

Volume Ratio:1.03

T/O Rate:0.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:1.64

PE(LYR):-1.12

Loading ...

Overview Company News Filings

Evommune Earns Buy Rating on Late-Stage Pipeline Progress and Multiple Near-Term Clinical Catalysts

Evommune Q1 EPS $(0.64) Beats $(0.71) Estimate

Benzinga Earnings

Evommune publishes corporate presentation on chronic inflammation therapies portfolio

Evommune Q1 FY26 net loss widens to $21.7 million; revenue is no revenue

Press Release: Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Stifel Nicolaus Initiates Coverage on Evommune With Buy Rating, $54 Price Target

MT Newswires Live

Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis

Six new option listings on April 23rd

Evommune announces annual shareholder meeting via virtual webcast

BRIEF-Evommune Inc - Prospectus Filed For Resale Of Up To 4.5 Million Shares Of Evommune Common Stock By Selling Stockholders - SEC Filing

Evommune Inc - Prospectus Filed for Resale of up to 4.5 Mln Shares of Evommune Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Evommune, Inc. (EVMN), Sarepta Therapeutics (SRPT)

Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating

Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy

Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says

MT Newswires Live

Evommune Price Target Maintained With a $48.00/Share by RBC Capital

Evommune assumed with an Outperform at Oppenheimer

Evommune to host webinar on MRGPRX2 inhibition potential in migraine

Evommune: Buy Rating Backed by 2026 Catalyst Rich Pipeline and Differentiated MRGPRX2 Dermatology Franchise

Evommune price target lowered to $50 from $65 at H.C. Wainwright

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/EVMN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":12.53,"timestamp":1788271511680,"preClose":12.66,"halted":0,"volume":35490,"delay":0,"changeRate":-0.010268562401263885,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Trading","change":-0.13,"latestTime":"09-01 10:05:12 EDT","open":12.6,"high":12.6,"low":12.44,"amount":444257.07690000004,"amplitude":0.012638,"askPrice":12.61,"askSize":31,"bidPrice":12.45,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.609,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":12.66,"preHourTrading":{"tag":"盘前","latestPrice":12.45,"preClose":12.66,"latestTime":"08:36 EDT","volume":162,"amount":2056.210353,"timestamp":1788266201339,"change":-0.21,"changeRate":-0.016588,"amplitude":0.019747},"postHourTrading":{"tag":"盘后","latestPrice":12.66,"preClose":12.66,"latestTime":"19:36 EDT","volume":44185,"amount":559381.883,"timestamp":1788219387436,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.034413,"impliedVol":1.805,"impliedVolPercentile":0.8462},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":1.034413,"shares":36292113,"dividePrice":0,"high":12.6,"amplitude":0.012638,"preClose":12.66,"low":12.44,"week52Low":10.47,"pbRate":"1.64","psRate":"45.47","week52High":33.2,"institutionHeld":0,"latestPrice":12.53,"committee":0.526718,"eps":-2.609,"divideRate":0,"volume":35490,"delay":0,"ttmEps":-2.609,"open":12.6,"prevYearClose":17.12,"prevWeekClose":13.23,"prevMonthClose":12.66,"prevQuarterClose":13.29,"fiveDayClose":13.79,"twentyDayClose":13.11,"sixtyDayClose":19.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5833,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1787976000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-08-31","current":-4.804523,"percent":1,"low":-16.229076,"twenty":-12.40534,"median":-9.712404,"eighty":-6.403835,"high":-5.071879,"avg":-9.852269,"sd":2.850991,"marketCap":480144654},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973},{"date":"2026-08-28","current":-5.16772,"twenty":-12.413708,"median":-9.712404,"eighty":-6.987812,"marketCap":489217683},{"date":"2026-08-31","current":-5.071879,"twenty":-12.40534,"median":-9.712404,"eighty":-6.403835,"marketCap":480144654}],"updateTime":1788271512143},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633101500","title":"Evommune Earns Buy Rating on Late-Stage Pipeline Progress and Multiple Near-Term Clinical Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2633101500","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633101500?lang=en_us&edition=fundamental","pubTime":"2026-05-08 08:36","pubTimestamp":1778200578,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on EVMN stock, giving a Buy rating on May 1. Matt Phipps has given his Buy ra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/evommune-earns-buy-rating-on-late-stage-pipeline-progress-and-multiple-near-term-clinical-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/evommune-earns-buy-rating-on-late-stage-pipeline-progress-and-multiple-near-term-clinical-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","SSI","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633172317","title":"Evommune Q1 EPS $(0.64) Beats $(0.71) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633172317","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633172317?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:38","pubTimestamp":1778186305,"startTime":"0","endTime":"0","summary":"Evommune (NYSE:EVMN) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.71) by 9.86 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52392411/evommune-q1-eps-0-64-beats-0-71-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Evommune Q1 EPS $(0.64) Beats $(0.71) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171859","title":"Evommune publishes corporate presentation on chronic inflammation therapies portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171859","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171859?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:16","pubTimestamp":1778184964,"startTime":"0","endTime":"0","summary":"Evommune investor deck highlighted two lead Phase 2 assets, led by EVO756, an oral MRGPRX2 antagonist positioned for mast cell-mediated disease and neuroinflammation.EVO756 Phase 2b catalysts set for chronic spontaneous urticaria data in June 2026, atopic dermatitis data in Q3 2026; migraine Phase 2b trial initiation targeted for mid-2026 with topline data in 2027.Earlier Phase 2 chronic inducible urticaria study in 30 adults showed 30% complete response at week 4 across 300 mg QD and 50 mg BID dosing; 70% achieved at least 1-point improvement on FricTest.Safety summary for EVO756 cited no serious adverse events or discontinuations; two subjects on 300 mg QD had asymptomatic ALT/AST elevations that later returned to baseline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL58wVgJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171866","title":"Evommune Q1 FY26 net loss widens to $21.7 million; revenue is no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171866","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171866?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:15","pubTimestamp":1778184955,"startTime":"0","endTime":"0","summary":"Evommune posted a net loss of USD 21.7 million, widening from USD 14.6 million a year earlier, with net loss per share narrowing to USD 0.64 from USD 9.48.No revenue versus USD 3 million a year earlier, while research and development expense climbed to USD 17.3 million from USD 14.4 million.General and administrative expense rose to USD 6.6 million from USD 3.7 million; cash, cash equivalents and investments increased to USD 307 million as of March 31, 2026 from USD 216.7 million at end-2025.Enrollment completed in Phase 2b dose-ranging trials of EVO756 in chronic spontaneous urticaria and atopic dermatitis, with top-line data expected in June 2026 and 3Q26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the ori","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL3pSYWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633179889","title":"Press Release: Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633179889","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633179889?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184300,"startTime":"0","endTime":"0","summary":"-- Phase 2b top-line data from EVO756 in chronic spontaneous urticaria  and atopic dermatitis  on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials. -- Phase 2b clinical trial evaluating a subcutaneous formulation of EVO301 in AD planned, following positive proof-of-concept  data reported in February 2026. -- Plans to initiate a Phase 2b dose-ranging clinical trial of EVO756 in migraine prophylaxis in mid-2026. PALO ALTO, Calif. & NEW YORK----May 07, 2026--. Evommune, Inc.  , a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.--  Upcoming Phase 2b Top-Line Data Readout in CSU: Enrollment is complete. in a Phase 2b dose-ranging clinical trial  in moderate-to-severe. AD patients and the Company expects to report top-line results in the. Development Program: The Company r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","SID","EVMN","BK4006","BK4139","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632194656","title":"Stifel Nicolaus Initiates Coverage on Evommune With Buy Rating, $54 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2632194656","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632194656?lang=en_us&edition=fundamental","pubTime":"2026-05-01 19:11","pubTimestamp":1777633870,"startTime":"0","endTime":"0","summary":"Evommune, Inc. (EVMN) has an average rating of Buy and mean price target of $52, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SF","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630809396","title":"Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2630809396","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630809396?lang=en_us&edition=fundamental","pubTime":"2026-04-26 00:30","pubTimestamp":1777134657,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ($EVMN) announced an update on their ongoing clinical study. The Phase 2b study of EVO756 in adults with atopic dermatitis is design...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-phase-2b-trial-an-emerging-catalyst-in-atopic-dermatitis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-phase-2b-trial-an-emerging-catalyst-in-atopic-dermatitis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629879834","title":"Six new option listings on April 23rd","url":"https://stock-news.laohu8.com/highlight/detail?id=2629879834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629879834?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:38","pubTimestamp":1776947900,"startTime":"0","endTime":"0","summary":"New option listings for April 23rd include REalloys Inc (ALOY), Arxis, Inc. (ARXS), Aevex Corp. (AVEX), Evommune Inc (EVMN), Brazil Potash Corp (GR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/six-new-option-listings-on-april-23rd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/six-new-option-listings-on-april-23rd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRO","BK4093","ARXS","EVMN","BK4139","ALOY","AVEX","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629057232","title":"Evommune announces annual shareholder meeting via virtual webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2629057232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629057232?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:06","pubTimestamp":1776802016,"startTime":"0","endTime":"0","summary":"Evommune schedules annual stockholders meeting for June 2, 2026, held virtually.Shareholders will vote to elect two Class I directors: Luis Pea, Eugene A. Bauer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL3xTnW1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628492784","title":"BRIEF-Evommune Inc - Prospectus Filed For Resale Of Up To 4.5 Million Shares Of Evommune Common Stock By Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2628492784","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628492784?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:40","pubTimestamp":1776458421,"startTime":"0","endTime":"0","summary":"BRIEF-Evommune Inc - Prospectus Filed For Resale Of Up To 4.5 Million Shares Of Evommune Common Stock By Selling Stockholders - SEC FilingApril 17  - Evommune Inc EVMN.N:EVOMMUNE INC - PROSPECTUS FILED FOR RESALE OF UP TO 4.5 MILLION SHARES OF EVOMMUNE COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILINGSource text: []Further company coverage: EVMN.N ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nFWN4100KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628814207","title":"Evommune Inc - Prospectus Filed for Resale of up to 4.5 Mln Shares of Evommune Common Stock by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2628814207","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628814207?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:07","pubTimestamp":1776456431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nFWN4100KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628277083","title":"Analysts Are Bullish on Top Healthcare Stocks: Evommune, Inc. (EVMN), Sarepta Therapeutics (SRPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628277083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628277083?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:20","pubTimestamp":1776421208,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evommune, Inc. (EVMN) and Sarepta Therapeutics (SRPT...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-evommune-inc-evmn-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-evommune-inc-evmn-sarepta-therapeutics-srpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4137","IE00BFTCPJ56.SGD","LU0029874061.USD","EVMN","BK4588","IE00BJT1NW94.SGD","SRPT","IE0009355771.USD","BLSX","BK4585","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4581","IE0002141913.USD","BLSG","SRPU","BK4112","BK4139","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627888469","title":"Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2627888469","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627888469?lang=en_us&edition=fundamental","pubTime":"2026-04-14 05:35","pubTimestamp":1776116121,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on EVMN stock, giving a Buy rating on April 10. Matt Phipps has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/evommune-differentiated-mrgprx2-strategy-and-upcoming-evo756-phase-iib-readout-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/evommune-differentiated-mrgprx2-strategy-and-upcoming-evo756-phase-iib-readout-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627654004","title":"Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2627654004","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627654004?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:36","pubTimestamp":1776112583,"startTime":"0","endTime":"0","summary":"An update from Evommune, Inc. ( ($EVMN) ) is now available. On April 13, 2026, Evommune hosted a webcast detailing the migraine treatment landscape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommune-spotlights-evo756-as-novel-preventive-migraine-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommune-spotlights-evo756-as-novel-preventive-migraine-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626791119","title":"Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2626791119","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626791119?lang=en_us&edition=fundamental","pubTime":"2026-04-10 23:45","pubTimestamp":1775835923,"startTime":"0","endTime":"0","summary":"Evommune's  experimental drug for chronic hives may have broader uses if upcoming trial results show it's both safe and effective, RBC Capital Markets said Friday in a report.The company's MRGPRX2 antagonist EVO756 has about a 50% chance of working on chronic spontaneous urticaria, or CSU, based on early signs that it reaches the right tissues and hits its intended target, RBC said. There's no direct CSU data yet, though the drug's exposure levels and results from a related challenge test support optimism, the report said.If the CSU study reads out positively later this quarter, RBC said EVO756 may also be tested in other conditions linked to overactive immune cells, including migraine, interstitial cystitis, and other inflammatory disorders. The CSU market is estimated at $850 million, with migraine representing a larger commercial opportunity, the report said.Some investor skepticism persists around EVO756, though its early data and tissue-targeting signals support for a more constru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626115427","title":"Evommune Price Target Maintained With a $48.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2626115427","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626115427?lang=en_us&edition=fundamental","pubTime":"2026-04-10 22:13","pubTimestamp":1775830380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 10:13 ET (14:13 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625524959","title":"Evommune assumed with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625524959","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625524959?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:18","pubTimestamp":1775571481,"startTime":"0","endTime":"0","summary":"Oppenheimer assumed coverage of Evommune (EVMN) with an Outperform rating and $50 price target The firm says investor focus is on Q2 readout in chr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-assumed-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-assumed-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625671703","title":"Evommune to host webinar on MRGPRX2 inhibition potential in migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2625671703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625671703?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:00","pubTimestamp":1775480450,"startTime":"0","endTime":"0","summary":"Evommune will host a KOL webinar on April 13, 2026 at 11:00 a.m. PT  focused on migraine treatment landscape and MRGPRX2 inhibition.Webinar will feature presentations from Stewart Tepper and Greg Dussor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire  on April 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL4czBty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620341552","title":"Evommune: Buy Rating Backed by 2026 Catalyst Rich Pipeline and Differentiated MRGPRX2 Dermatology Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2620341552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620341552?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:16","pubTimestamp":1773828963,"startTime":"0","endTime":"0","summary":"Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Evommune, Inc.. The associated price target was lowered to $50.00. M...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/evommune-buy-rating-backed-by-2026-catalyst-rich-pipeline-and-differentiated-mrgprx2-dermatology-franchise-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/evommune-buy-rating-backed-by-2026-catalyst-rich-pipeline-and-differentiated-mrgprx2-dermatology-franchise-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620234436","title":"Evommune price target lowered to $50 from $65 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2620234436","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620234436?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:12","pubTimestamp":1773828734,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Evommune (EVMN) to $50 from $65 and keeps a Buy rating on the shares. The firm cites the company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-50-from-65-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-50-from-65-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":91,"code":"91000000","status":"200"}]}}